Description
Treatment of Chronic Lymphocytic Leukaemia and Follicular Lymphoma has undergone significant evolution over the last decade with the advent of rituximab. Since then, a new class of targeted therapies has been developed which offers the possibility of a paradigm shift in this disease, with greater effectiveness in prolongation of progression-free survival compared to standard therapies.